Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

To put this spike into perspective, the rural city of around 32,000 people has now recorded more HIV cases in two years than ...

Merck on Wednesday said the Phase 3 study of the once-daily, two-drug single-tablet regimen met the success criterion for its primary efficacy hypothesis, showing non-inferiority to the three-drug ...

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said the treatment is a once-daily two-drug regimen of doravirine/islatravir that ...

Organizations that provide services like HIV education and living recommendations are being forced to cut programming after ...

Medicaid expansion under the Affordable Care Act (ACA) significantly increased the number of people at risk of HIV diagnosis ...

Local political activists put their heads together after first case of infection confirmed in 18-month-old girl.